Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: Results from the ESPOIR cohort

Arthritis Research and Therapy

Volumn 15, Issue 6, 2013, Pages

  Meyer, Magali ^a,b,c   Sellam, Jérémie ^a,b,c   Fellahi, Soraya ^b,c,d   Kotti, Salma ^a   Bastard, Jean Philippe ^b,c,d   Meyer, Olivier ^e   Lioté, Frédéric ^e   Simon, Tabassome ^a,b   Capeau, Jacqueline ^b,c,d   Berenbaum, Francis ^a,b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d HÔPITAL TENON   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AUTOANTIBODY; C REACTIVE PROTEIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; STEROID; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; ARTICLE; DAS28; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRESCRIPTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; BLOOD; COHORT ANALYSIS; RADIOGRAPHY;

ADIPONECTIN; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84891896499     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4404     Document Type: Article

References (43)

1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 2010:2569-2581.
2. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451. 10.1016/S0002-9343(01)00872-5, 11690569.
3. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201. 10.1136/ard.2003.019992, 1755350, 15458956.
4. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R949-958. 10.1186/ar1767, 1257421, 16207336.
5. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, Daragon A, Tron F, Le Loet X. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford) 2003, 42:939-946. 10.1093/rheumatology/keg257, 12730503.
6. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, Group BS. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095. 10.1136/ard.2003.014233, 1755129, 15308518.
7. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3:716-724. 10.1038/ncprheum0674, 18037931.
8. Scotece M, Conde J, Gómez R, López V, Pino J, González A, Lago F, Gómez-Reino JJ, Gualillo O. Role of adipokines in atherosclerosis: interferences with cardiovascular complications in rheumatic diseases. Mediators Inflamm 2012, 2012:125458. 3403095, 22910888.
9. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
10. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. Ann Intern Med 2008, 149:307-316. 10.7326/0003-4819-149-5-200809020-00005, 3874083, 18765700.
11. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Fève B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
12. Hascoet S, Elbaz M, Bongard V, Bouisset F, Verdier C, Vindis C, Annelise G, Taraszkiewicz D, Perret B, Galinier M, Carrié D, Ferrières J, Ruidavets JB. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler Thromb Vasc Biol 2012, 33:e19-29.
13. Jia T, Carrero JJ, Lindholm B, Stenvinkel P. The complex role of adiponectin in chronic kidney disease. Biochimie 2012, 94:2150-2156. 10.1016/j.biochi.2012.02.024, 22980197.
14. Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, Vionnet N, Rossing P. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008, 74:649-654. 10.1038/ki.2008.201, 18496510.
15. Pham MN, Kolb H, Mandrup-Poulsen T, Battelino T, Ludvigsson J, Pozzilli P, Roden M, Schloot NC, Trial EC. Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes Metab Res Rev 2013, 29:166-170. 10.1002/dmrr.2378, 23197433.
16. Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009, 29:1431-1438. 10.1111/j.1478-3231.2009.02022.x, 19422483.
17. Neumann E, Frommer KW, Vasile M, Muller-Ladner U. Adipocytokines as driving forces in rheumatoid arthritis and related inflammatory diseases?. Arthritis Rheum 2011, 63:1159-1169. 10.1002/art.30291, 21337317.
18. Giles JT, Allison M, Bingham CO, Scott WM, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009, 61:1248-1256. 10.1002/art.24789, 2759038, 19714593.
19. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, Shintani A, Pincus T, Stein CM. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009, 60:1906-1914. 10.1002/art.24626, 2894567, 19565493.
20. Klein-Wieringa IR, van der Linden MP, Knevel R, Kwekkeboom JC, van Beelen E, Huizinga TW, van der Helm-van Mil A, Kloppenburg M, Toes RE, Ioan-Facsinay A. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011, 63:2567-2574. 10.1002/art.30449, 21567382.
21. Giles JT, van der Heijde DM, Bathon JM. Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1562-1568. 10.1136/ard.2011.150813, 3543946, 21571734.
22. Combe B, Benessiano J, Berenbaum F, Cantagrel A, Daures JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loet X, Logeart I, Mariette X, Meyer O, Ravaud P, Rincheval N, Saraux A, Schaeverbeke T, Sibilia J. The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients. Joint Bone Spine 2007, 74:440-445. 10.1016/j.jbspin.2007.06.001, 17905631.
23. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009, 11:R114. 10.1186/ar2773, 2745796, 19627580.
24. Devauchelle-Pensec V, Berthelot JM, Jousse S, Samjee I, Josseaume T, Colin D, Chales G, Thorel JB, Hoang S, Martin A, Youinou P, Le Goff P, Saraux A. Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol 2006, 33:1511-1515.
25. Gottenberg JE, Dayer JM, Lukas C, Ducot B, Chiocchia G, Cantagrel A, Saraux A, Roux-Lombard P, Mariette X. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2012, 71:1243-1248. 10.1136/annrheumdis-2011-200975, 22532637.
26. Sellam J, Kotti S, Fellahi S, Bastard JP, Meyer M, Lioté F, Meyer O, Simon T, Capeau J, Berenbaum F. Serum hepcidin level is not an independent surrogate biomarker of disease activity or severity in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis 2013, 72:312-314. 10.1136/annrheumdis-2012-202119, 23148308.
27. Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther 2012, 14:R249. 10.1186/ar4092, 3674616, 23164197.
28. Youden WJ. An index for rating diagnostic tests. Cancer 1950, 3:32-35. 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3, 15405679.
29. Ehling A, Schaffler A, Herfarth H, Tarner IH, Anders S, Distler O, Paul G, Distler J, Gay S, Scholmerich J, Neumann E, Müller-Ladner U. The potential of adiponectin in driving arthritis. J Immunol 2006, 176:4468-4478.
30. Frommer KW, Zimmermann B, Meier FM, Schroder D, Heil M, Schaffler A, Buchler C, Steinmeyer J, Brentano F, Gay S, Müller-Ladner U, Neumann E. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010, 62:2886-2899. 10.1002/art.27616, 20564003.
31. Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, Tzeng CY, Chen KH, Chiu YC, Tang CH. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 2011, 112:1431-1440. 10.1002/jcb.23059, 21321996.
32. Lago R, Gomez R, Otero M, Lago F, Gallego R, Dieguez C, Gomez-Reino JJ, Gualillo O. A new player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008, 16:1101-1109. 10.1016/j.joca.2007.12.008, 18261936.
33. Chen X, Lu J, Bao J, Guo J, Shi J, Wang Y. Adiponectin: a biomarker for rheumatoid arthritis?. Cytokine Growth Factor Rev 2013, 24:83-89. 10.1016/j.cytogfr.2012.07.004, 22910140.
34. Kusunoki N, Kitahara K, Kojima F, Tanaka N, Kaneko K, Endo H, Suguro T, Kawai S. Adiponectin stimulates prostaglandin E(2) production in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010, 62:1641-1649. 10.1002/art.27450, 20222108.
35. Frommer KW, Schaffler A, Buchler C, Steinmeyer J, Rickert M, Rehart S, Brentano F, Gay S, Muller-Ladner U, Neumann E. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?. Ann Rheum Dis 2012, 71:1724-1732. 10.1136/annrheumdis-2011-200924, 22532632.
36. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006, 21:1648-1656. 10.1359/jbmr.060707, 16995820.
37. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83. 10.1006/bbrc.1999.0255, 10092513.
38. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278. 10.1042/CS20050182, 16464169.
39. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care 2007, 30:1200-1205. 10.2337/dc06-2416, 17322479.
40. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008, 67:769-774. 10.1136/ard.2007.078832, 17965124.
41. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007, 56:3575-3582. 10.1002/art.23033, 17968909.
42. Fardet L, Antuna-Puente B, Vatier C, Cervera P, Touati A, Simon T, Capeau J, Feve B, Bastard JP. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol (Oxf) 2013, 78:43-51. 10.1111/j.1365-2265.2012.04348.x, 22268638.
43. Sukumaran S, Dubois DC, Jusko WJ, Almon RR. Glucocorticoid effects on adiponectin expression. Vitam Horm 2012, 90:163-186. 3693220, 23017716.